Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ana Milena Millan"'
Autor:
Ivan Castellví, Diego Castillo, Hèctor Corominas, Anaís Mariscal, Sandra Orozco, Natividad Benito, Virginia Pomar, Andrés Baucells, Isabel Mur, David de la Rosa-Carrillo, David Lobo, Ana Milena Millan, Nerea Hernández de Sosa, David Filella, Laia Matas, Laura Martínez-Martínez, Cándido Juarez, Jordi Casademont, Pere Domingo
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Coronavirus disease 2019 (COVID-19) has rapidly expanded worldwide. Currently, there are no biomarkers to predict respiratory worsening in patients with mild to moderate COVID-19 pneumonia. Small studies explored the use of Krebs von de Lungen-6 circ
Externí odkaz:
https://doaj.org/article/c7d43db410004423b9c0ce430cda69db
Autor:
Carlos Sanchez-Piedra, M. Victoria Hernández Miguel, Javier Manero, Rosa Roselló, Jesús Tomás Sánchez-Costa, Carlos Rodríguez-Lozano, Cristina Campos, Eduardo Cuende, Jesús Carlos Fernández-Lopez, Sagrario Bustabad, Raquel Martín Domenech, Eva Pérez-Pampín, Javier del Pino-Montes, Ana Milena Millan-Arciniegas, Federico Díaz-González, Juan Jesús Gómez-Reino
Publikováno v:
Reumatología Clínica (English Edition). 15:229-236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2333b0f38286e2cdb76de28c00b96eb
https://doi.org/10.1016/j.reumae.2017.08.005
https://doi.org/10.1016/j.reumae.2017.08.005
Autor:
Eduardo Cuende, M. Victoria Hernández Miguel, Raquel Martín Domenech, Rosa Roselló, Jesús T. Sánchez-Costa, Carlos Sánchez-Piedra, Javier del Pino-Montes, Jesús Carlos Fernández-Lopez, Carlos Rodríguez-Lozano, Ana Milena Millan-Arciniegas, Javier Manero, Eva Perez-Pampin, en representación del Grupo de trabajo Biobadaser Fase, Juan J. Gomez-Reino, Sagrario Bustabad, Federico Díaz-González, Cristina Campos
Publikováno v:
Reumatología Clínica. 15:229-236
Objective Describe the objectives, methods and results of the first year of the new version of the Spanish registry of adverse events involving biological therapies and synthetic drugs with an identifiable target in rheumatic diseases (BIOBADASER III
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2af93ac61953c02a7f7ee7d34b76908
https://doi.org/10.1016/j.reuma.2017.08.001
https://doi.org/10.1016/j.reuma.2017.08.001
Autor:
Alicia Alonso-Jimenez, Eduard Gallardo, Ana Milena-Millan, Hèctor Corominas, Ana Carrasco-Rozas, Laura Martínez-Martínez, Ricardo Rojas-García, Carlos Zamora, Xavier Suárez-Calvet, Diego Castillo, Isabel Illa, Ivan Castellví, Elena Cortés-Vicente, Luis Querol, Jorge Alonso-Pérez, Noemi de Luna, Jordi Díaz-Manera, Joana Turón, Esther Fernández-Simón
Publikováno v:
Neurology-Neuroimmunology & Neuroinflammation
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Neurology® Neuroimmunology & Neuroinflammation
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Neurology® Neuroimmunology & Neuroinflammation
ObjectiveTo describe the clinical, serologic and histologic features of a cohort of patients with brachio-cervical inflammatory myopathy (BCIM) associated with systemic sclerosis (SSc) and unravel disease-specific pathophysiologic mechanisms occurrin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e335ecfea5fb7da4b2b627e11f72669
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1878
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1878
Autor:
Carlos, Sanchez-Piedra, M Victoria, Hernández Miguel, Javier, Manero, Rosa, Roselló, Jesús Tomás, Sánchez-Costa, Carlos, Rodríguez-Lozano, Cristina, Campos, Eduardo, Cuende, Jesús Carlos, Fernández-Lopez, Sagrario, Bustabad, Raquel, Martín Domenech, Eva, Pérez-Pampín, Javier, Del Pino-Montes, Ana Milena, Millan-Arciniegas, Federico, Díaz-González, Juan Jesús, Gómez-Reino
Publikováno v:
Reumatologia clinica. 15(4)
Describe the objectives, methods and results of the first year of the new version of the Spanish registry of adverse events involving biological therapies and synthetic drugs with an identifiable target in rheumatic diseases (BIOBADASER III).Multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fbb4a00d090437c2a8c3c1b71e0fe880
https://pubmed.ncbi.nlm.nih.gov/28935290
https://pubmed.ncbi.nlm.nih.gov/28935290
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cardiovascular Week; 4/15/2024, p354-354, 1p
Autor:
Suárez-Calvet, Xavier, Alonso-Pérez, Jorge, Castellví, Ivan, Carrasco-Rozas, Ana, Fernández-Simón, Esther, Zamora, Carlos, Martínez-Martínez, Laura, Alonso-Jiménez, Alicia, Rojas-García, Ricardo, Turón, Joana, Querol, Luis, de Luna, Noemi, Milena-Millan, Ana, Corominas, Héctor, Castillo, Diego, Cortés-Vicente, Elena, Illa, Isabel, Gallardo, Eduard, Díaz-Manera, Jordi
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation; May2020, Vol. 7 Issue 3, p1-12, 12p
Publikováno v:
Immunotherapy Weekly; 2/7/2023, p2033-2033, 1p
Autor:
Hèctor Corominas, Berta Magallares, Raul Castellanos-Moreira, Millán Arciniegas Ana Milena, David Lobo, José A. Gómez-Puerta, Sebastian C. Rodriguez-García, Patricia Moya, Ivan Castellví, Virginia Ruiz-Esquide, Roberto Gumucio, Ana Laiz, Cesar Diaz-Torne
Publikováno v:
Other orphan diseases.
Background Immune checkpoint inhibitors (ICI) against CTLA-4 or PD-1/PD-L1 improve the survival of patients with advanced malignancies including melanoma, lung cancer among other tumours. Because of its mechanism of action, ICI are prone to produce d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca093f99be28c9363414882917382706
https://doi.org/10.1136/annrheumdis-2019-eular.301
https://doi.org/10.1136/annrheumdis-2019-eular.301